gdc

Prostate Cancer

How I Learned to Be Vulnerable: Sharing My Prostate Cancer Story Helped My Healing
Patient StoriesProstate CancerSurvivorship
A decade after his son passed away from a rare form of bone cancer at age 16, Mark DeLong was diagnosed with prostate cancer. He learned, among other things, the healing power of being vulnerable and sharing personal stories.
Your Prostate Gland, Your Responsibility: Understanding the Risks, Diagnosis, and Treatment Options for Prostate Cancer
Prostate CancerMen's Health
Dr. Daniel Vorobiof provides an overview of prostate cancer, including prevention tips and risk factors, diagnosis, treatment options, and specific questions to consider asking your doctor.
Racial Disparities in Prostate Cancer Outcomes Not Caused by Biological Differences
Racial DisparitiesProstate CancerDiagnosis
A breakdown of recent studies that shed light on racial disparities in the treatment of black and white men who are diagnosed with prostate cancer.
Providing Men a New, Safer Way of Diagnosing Prostate Cancer
Prostate CancerDiagnosisMen's Health
Dr. Matthew Allaway is a testicular cancer survivor and a practicing urologist. Here, he describes a new procedure he crated to ease the difficulty of diagnosing prostate cancer, the most common cancer among men in the United States.
Orgovyx First FDA-Approved Oral Hormone Therapy for Patients with Advanced Prostate Cancer
FDA Approvals, News & UpdatesProstate Cancer
In December 2020, the FDA approved Orgovyx (relugolix), as the first oral hormone therapy for the treatment of men with advanced prostate cancer. This new drug may eliminate the need to visit the clinic for treatment, helping patients with cancer avoid unnecessary exposure during the pandemic.
Drugs for Prostate Cancer
Prostate Cancer
Here are the drugs and financial support services available to patients receiving treatment for Prostate Cancer.
Lynparza Improves Quality of Life in Men with Metastatic Prostate Cancer
Prostate Cancer
The PARP inhibitor Lynparza (olaparib), a type of drug that is usually used for the treatment of women with ovarian cancer, has also been studied in men with prostate cancer. The results of the PROfound clinical trial were recently presented at the 2020 ASCO annual meeting by Antoine Thiery-Vuillemin, MD, PhD, Centre Hospitalier de Besançon, France.
The Combination of Cabometyx plus Tecentriq Improves Outcomes in Patients with Advanced Prostate Cancer
Prostate Cancer
Results of a new study showed that the combination of Cabometyx (cabozantinib) and the immune checkpoint inhibitor Tecentriq (atezolizumab) was safe and effective in men with metastatic (spreading) castration-resistant prostate cancer, the most common type of prostate cancer.
Page 1 of 3
Results 1 - 10 of 25

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country
Gender
Race or Ethnicity
Profession or Role
Primary Interest